Production of Zr-89 using sputtered yttrium coin targets

Queern, Stacy L.; Aweda, Tolulope; Massicano, Adriana V F; Clanton, Nicholas A; Sayed, Retta El; Sader, Jayden A.; Zyuzin, A. Yu.; Lapi, Suzanne E.

doi:10.1016/j.nucmedbio.2017.03.004

Cited by 51 publications

(57 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The target material is monoisotopic, making it economical with straightforward chemistry, as the target material does not have to be recycled. Targets have been prepared using foils, pressed powders, and sputtered material . The production of this radionuclide via the irradiation of dissolved yttrium salts has also been investigated .…”

Section: Radiometals For Theranostic Applicationsmentioning

confidence: 99%

“…Targets have been prepared using foils, pressed powders, and sputtered material. 108,109 The production of this radionuclide via the irradiation of dissolved yttrium salts has also been investigated. 110 Irradiations with protons <14 MeV are typically used to prevent the coproduction of 88 Zr, an undesirable long-lived impurity.…”

Section: Zrmentioning

confidence: 99%

“…After the target is irradiated, the Y target material is typically dissolved in HCl and purified from the target material by passing it through a hydroxamate resin. 108,111 HCl and water are used to elute the target material, and the 89 Zr is eluted in oxalic acid. The oxalic acid is typically removed after the radiolabelling process by size exclusion chromatography.…”

Section: Zrmentioning

confidence: 99%

See 2 more Smart Citations

Radiometals for imaging and theranostics, current production, and future perspectives

Mikołajczak

Meulen

Lapi

2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The aim of this review is to make the reader familiar with currently available radiometals, their production modes, capacities, and quality concerns related to their medical use, as well as new emerging radiometals and irradiation technologies from the perspective of their diagnostic and theranostic applications. Production methods of 177Lu serve as an example of various issues related to the production yield, specific activity, radionuclidic and chemical purity, and production economy. Other radiometals that are currently used or explored for potential medical applications, with particular focus on their theranostic value, are discussed. Using radiometals for diagnostic imaging and therapy is on the rise. The high demand for radiometals for medical use prompts investigations towards using alternative irradiation reactions, while using existing nuclear reactors and accelerator facilities. This review discusses these production capacities and what is necessary to cover the growing demand for theranostic nuclides.

show abstract

Section: Radiometals For Theranostic Applicationsmentioning

confidence: 99%

Section: Zrmentioning

confidence: 99%

Section: Zrmentioning

confidence: 99%

See 1 more Smart Citation

Radiometals for imaging and theranostics, current production, and future perspectives

Mikołajczak

Meulen

Lapi

2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

“…The target coin prototypes were realized fitting the design of the corresponding target station, which means disks of 2 mm maximum thickness and diameters of 32 mm (TEMA) and 24 mm (ACSI). TR19 [14][15][16][17][18][19] MeV is a variable energy proton cyclotron with a high current ion source up to 300 µA. The corresponding ACSI solid target station allows for direct helium gas cooling of the target coin from the front part and water cooling from the back.…”

Section: Cyclotron Testsmentioning

confidence: 99%

“…Here, we have associated with the group of physical methods different Physical Vapor Deposition (PVD) methods, such as Focused Ion Beam (FIB) or magnetron sputtering, thermal spray deposition, and plasma spray deposition. Table 1 presents a summary of the most commonly used methods for cyclotron solid target preparation and some examples of their [3,[19][20][21][22][23][24] In order to maximize the nuclear reaction yield, production should be performed at maximum proton currents. This means that the target system should provide high efficiency of heat dissipation.…”

Section: Introductionmentioning

confidence: 99%

Medical Cyclotron Solid Target Preparation by Ultrathick Film Magnetron Sputtering Deposition

et al. 2019

View full text Add to dashboard Cite

Magnetron sputtering is proposed here as an innovative method for the deposition of a material layer onto an appropriate backing plate for cyclotron solid targets aimed at medical radioisotopes production. In this study, a method to deposit thick, high-density, high-thickness-uniformity, and stress-free films of high adherence to the backing was developed by optimizing the fundamental deposition parameters: sputtering gas pressure, substrate temperature, and using a multilayer deposition mode, as well. This method was proposed to realize Mo-100 and Y-nat solid targets for biomedical cyclotron production of Tc-99m and Zr-89 radionuclides, respectively. The combination of all three optimized sputtering parameters (i.e., 1.63 × 10−2 mbar Ar pressure, 500 °C substrate temperature, and the multilayer mode) allowed us to achieve deposition thickness as high as 100 µm for Mo targets. The 50/70-µm-thick Y targets were instead realized by optimizing the sputtering pressure only (1.36 × 10−2 mbar Ar pressure), without making use of additional substrate heating. These optimized deposition parameters allowed for the production of targets by using different backing materials (e.g., Mo onto copper, sapphire, and synthetic diamond; and Y onto a niobium backing). All target types tested were able to sustain a power density as high as 1 kW/cm2 provided by the proton beam of medical cyclotrons (15.6 MeV for Mo targets and 12.7 MeV for Y targets at up to a 70-µA proton beam current). Both short- and long-time irradiation tests, closer to the real production, have been realized.

show abstract

⁸⁹Zr‐ImmunoPET companion diagnostics and their impact in clinical drug development

McKnight

Viola-Villegas

2018

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Therapeutic monoclonal antibodies have been used in cancer treatment for 30 years, with around 24 mAb and mAb:drug conjugates approved by the FDA to date. Despite their specificity, efficacy has remained limited, which, in part, derails nascent initiatives towards precision medicine. An image-guided approach to reinforce treatment decisions using immune positron emission tomography (immunoPET) companion diagnostic is warranted. This review provides a general overview of current translational research using Zr-89 immunoPET and opportunities for utilizing and harnessing this tool to its full potential. Patient case studies are cited to illustrate immunoPET probes as tools for profiling molecular signatures. Discussions on its utility in reinforcing clinical decisions as it relates to histopathological tumor assessment and standard diagnostic methods, and its potential as predictive biomarkers, are presented. We finally conclude with an overview of practical considerations to its utility in the clinic.

show abstract

Production of Zr-89 using sputtered yttrium coin targets

Cited by 51 publications

References 17 publications

Radiometals for imaging and theranostics, current production, and future perspectives

Radiometals for imaging and theranostics, current production, and future perspectives

Medical Cyclotron Solid Target Preparation by Ultrathick Film Magnetron Sputtering Deposition

⁸⁹Zr‐ImmunoPET companion diagnostics and their impact in clinical drug development

Contact Info

Product

Resources

About

Production of Zr-89 using sputtered yttrium coin targets

Cited by 51 publications

References 17 publications

Radiometals for imaging and theranostics, current production, and future perspectives

Radiometals for imaging and theranostics, current production, and future perspectives

Medical Cyclotron Solid Target Preparation by Ultrathick Film Magnetron Sputtering Deposition

89Zr‐ImmunoPET companion diagnostics and their impact in clinical drug development

Contact Info

Product

Resources

About

⁸⁹Zr‐ImmunoPET companion diagnostics and their impact in clinical drug development